Scientists Discover Antibody that Blocks 98% of HIV Strains
|
To date, even the best broadly neutralizing antibodies
(bnAbs)—special proteins that target multiple HIV strains—have shown
limits in clinical trials. |
AbbVie's HIV Study: A Potential Game Changer in HIV Treatment
... Antiretroviral Therapy Undergoing Analytical Treatment Interruption. The study aims to assess changes in disease activity, adverse events, and ... View article...